Alzheimer's disease (AD) is the most common form of dementia caused by neurodegenerative process and is tightly related to amyloid beta (Abeta) and neurofibrillary tangles. The lack of early diagnostic biomarker and therapeutic remedy hinders the prevention of increasing population of AD patients every year. In spite of accumulated scientific information, numerous clinical trials for candidate drug targets have failed to be preceded into therapeutic development, therefore, AD-related sufferers including patients and caregivers, are desperate to seek the solution. Also, effective AD intervention is desperately needed to reduce AD-related societal threats to public health. In this review, we summarize various drug targets and strategies in recent preclinical studies and clinical trials for AD therapy: Allopathic treatment, immunotherapy, Abeta production/aggregation modulator, tau-targeting therapy and metabolic targeting. Some has already failed in their clinical trials and the others are still in various stages of investigations, both of which give us valuable information for future research in AD therapeutic development.
Alzheimer Disease/immunology/pathology/*therapy ; Amyloid beta-Peptides/antagonists & inhibitors/immunology/metabolism ; Antibodies, Monoclonal/therapeutic use ; Brain/metabolism/pathology ; Humans ; Immunotherapy ; N-Methylaspartate/therapeutic use ; tau Proteins/antagonists & inhibitors/metabolism

Alzheimer's disease (AD) is the most common cause of dementia in elderly population. There are two hallmark pathological lesions: the intracellular neurofibrillary tangles (NFTs) and the extracellular amyloid deposits in the senile plaques (SP). The NFTs are aggregates of hyperphosphorylated microtubule Tau protein. The amyloid deposits in the SP are the beta-amyloid (Abeta) peptides-Abeta40 and Abeta42. The Abeta peptides are derived from the amyloid precursor protein (APP) which is considered very important for the AD pathogenesis. In recent years, studies have focused on understanding the generation of Abeta peptides by the alpha-, beta- and gamma- secretase activity on APP, as cause and progression of both familial and sporadic AD (FAD and SAD). This review covers the trafficking and processing of APP, the amyloid cascade hypothesis in AD pathogenesis, the mutations in the genes encoding APP, PS1 and PS2 of early-onset and late-onset AD. The risk factor apolipoprotein E (ApoE) for AD and therapeutic anti-beta-amyloid vaccination strategies for prevention of AD are also discussed.
Alzheimer Disease ; genetics ; metabolism ; pathology ; therapy ; Alzheimer Vaccines ; immunology ; Amyloid beta-Peptides ; antagonists & inhibitors ; genetics ; immunology ; metabolism ; Amyloid beta-Protein Precursor ; genetics ; metabolism ; Animals ; Apolipoproteins E ; genetics ; Humans ; Immunotherapy, Active ; Membrane Proteins ; genetics ; Peptide Fragments ; genetics ; Plaque, Amyloid ; pathology ; Presenilin-1 ; Presenilin-2